Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

57.46 +3.72 (+6.92%)
Streaming Delayed Price Updated: 11:55 AM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
26 27 Next >
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are helping change medicine; they could make boatloads of money along the way. 
Via The Motley Fool
3 Cathie Wood Stocks Set to Explode Higher
Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside. 
Via InvestorPlace
2 Bargain Growth Stocks to Buy Hand Over Fist
Both stocks have declined in recent times. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains. 
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
These stocks have what it takes to grow in leaps and bounds. 
Via The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
The FDA is within three months of making a decision on the first-ever CRISPR-based drug. 
Via Investor's Business Daily
Exposures Product Safety
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher. 
Via InvestorPlace
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
These two high-tech stocks could dramatically outperform the broader market in the years ahead. 
Via The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
I favor holding onto these players for the long term to truly benefit from their earnings potential. 
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 5 Years?
The company hasn't performed well in the past five years, but things could change. 
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Good medicines aren't always good business. 
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Early investors in these trends may reap the rewards over time. 
Via The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
Catalysts on the horizon could drive gains in these top stocks. 
Via The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
The returns are impressive, but will they continue to be so? 
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
3 Top Healthcare Stocks Defying the Bear Market
Revenue at all three companies improved last quarter, and their share prices have followed suit. 
Via The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
Investors may look for growth stocks ahead of the next bull market. 
Via The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
These companies are innovators, something that can prove highly lucrative. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.